The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus Uncoated Balloon Angioplasty by Scheinert, Dierk et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 3 . 0 5 . 0 2 2The LEVANT I (Lutonix Paclitaxel-Coated
Balloon for the Prevention of
Femoropopliteal Restenosis) Trial for
Femoropopliteal Revascularization
First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus
Uncoated Balloon Angioplasty
Dierk Scheinert, MD,* Stephan Duda, MD,y Thomas Zeller, MD,z
Hans Krankenberg, MD,x Jens Ricke, MD,k Marc Bosiers, MD,{ Gunnar Tepe, MD,#
Scott Naisbitt, MD, PHD,** Kenneth Rosenﬁeld, MDyy
Leipzig, Berlin, Bad Krozingen, Hamburg, Rosenheim, and Magdeburg, Germany;
Dendermonde, Belgium; New Hope, Minnesota; and Cambridge, MassachusettsFrom the *Center of Vascular Medicine, Heart Center Leipzig/Park Hospital, Leipzig, Germany; yCenter for Diagnostic Radiology
and Minimally Invasive Therapy, Jewish Hospital, Berlin, Germany; zDepartment of Interventional Angiology, Herz-Zentrum,
Bad Krozingen, Germany; xCardiovascular Center, Hamburg University Cardiovascular Center, Hamburg, Germany; kClinic for
Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany; {Flanders Medical Research Program,
JACC:CARDIOVASCULAR INTERVENTIONSCME
This article has been selected as this issue’s CME activity,
available online at http://interventions.onlinejacc.org/
by selecting the CME tab on the top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation (ACCF)
is accredited by the Accreditation Council for Continuing
Medical Education (ACCME) to provide continuing
medical education for physicians.
The ACCF designates this Journal-based CME activity
for a maximum of 1 AMA PRA Category 1 Credit(s).
Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Method of Participation and
Receipt of CME Certiﬁcate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular
Interventions subscriber.
2. Carefully read the CME-designated article available
online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3
questions provided must be answered correctly to obtain
CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certiﬁcate
electronically by following the instructions given at the
conclusion of the activity.
CME Objective for This Article:
At the completion of this article, the learner should be
able to:
1. Discuss the effect of drug-eluting carrier formulations on
the percutaneous treatment of peripheral vascular disease.
2. Deﬁne late lumen loss and explain why it was selected as
the primary endpoint.
3. Discuss reasons for failed balloon deployment and its
impact on sustained prevention of restenosis in target
lesions.
CME Editor Disclosure: JACC: Cardiovascular Interventions
CME Editor Habib Samady, MB, ChB, FACC, has
research grants from the Wallace H. Coulter Foundation,
Volcano Corp., St. Jude Medical, Forrest Pharmaceuticals
Inc., and Pﬁzer Inc.
Author Disclosure: This clinical trial was sponsored by
Lutonix, Inc., a subsidiary of C. R. Bard. Dr. Scheinert
serves on the scientiﬁc advisory board of Lutonix. Dr.
Duda has received study honorarium from Lutonix; and
formerly served on the LEVANT-I Steering
Committee. Dr. Zeller serves on the advisory boards to
Medtronic Invatec, Medtronic Ardian, W. L. Gore &
Associates, Angioslide, and Covedian-ev3; has received
consulting fees from C. R. Bard, Johnson & Johnson
Cordis, Boston Scientiﬁc, Straub Medical, Invatec, and
Biotronik; and has received research grants from Cook,
Krauth Medical, Abbott Vascular, and InnoRa. Dr.
Tepe consults for Abbott, Covidien, Medtronic, and
Medrad. Dr. Naisbitt is an employee of Lutonix,
a subsidiary of C. R. Bard. Dr. Rosenﬁeld consults for
Lutonix and Abbott Vascular. All other authors have
reported that they have no relationships relevant to the
contents of this paper to disclose.
Medium of Participation: Print (article only); online
(article and quiz).
CME Term of Approval:
Issue Date: January 2014
Expiration Date: December 31, 2014
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 1 , 2 0 1 4 Scheinert et al.
J A N U A R Y 2 0 1 4 : 1 0 – 9 Lutonix Paclitaxel-DCB for Femoropopliteal Revascularization
11The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization
First-in-Human Randomized Trial of Low-Dose Drug-Coated Balloon Versus
Uncoated Balloon AngioplastyObjectives This study sought to evaluate the safety and efﬁcacy of the Lutonix drug-coated balloon (DCB) coated with 2 mg/mm2
paclitaxel and a polysorbate/sorbitol carrier for treatment of femoropopliteal lesions.
Background Percutaneous treatment of peripheral vascular disease is associated with a high recurrence. Paclitaxel-coated balloons
at 3 mg/mm2 formulated differently have shown promising results with reduced restenosis.
Methods Subjects at 9 centers with Rutherford class 2 to 5 femoropopliteal lesions were randomized between June 2009 and
December 2009 to treatment with Lutonix DCB (n ¼ 49) versus uncoated balloons (control group [n ¼ 52]), stratiﬁed by whether
balloon-only treatment (n ¼ 75) or stenting (n ¼ 26) was intended. The primary endpoint was angiographic late lumen loss at
6 months. Secondary outcomes included adjudicated major adverse events (death, amputation, target lesion thrombosis,
reintervention), functional outcomes, and pharmacokinetics.
Results Demographic, peripheral vascular disease, and lesion characteristics were matched, with mean lesion length of 8.1  3.8
cm and 42% total occlusions. At 6 months, late lumen loss was 58% lower for the Lutonix DCB group (0.46  1.13 mm) than for the
control group (1.09  1.07 mm; p ¼ 0.016). Composite 24-month major adverse events were 39% for the DCB group, including
15 target lesion revascularizations, 1 amputation, and 4 deaths versus 46% for uncoated balloon group, with 20 target lesion
revascularizations, 1 thrombosis, and 5 deaths. Pharmacokinetics showed biexponential decay with peak concentration (Cmax) of 59
ng/ml and total observed exposure (AUCall) of 73 ng h/ml. For successful DCB deployment excluding 8 malfunctions, 6-month late
lumen loss was 0.39 mm and the 24-month target lesion revascularization rate was 24%.
Conclusions Treatment of femoropopliteal lesions with the low-dose Lutonix DCB reduced late lumen loss with safety comparable
to that of control angioplasty. (LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis;
NCT00930813) (J Am Coll Cardiol Intv 2014;7:10–9) ª 2014 by the American College of Cardiology FoundationPeripheral vascular disease, like coronary artery disease, is
a signiﬁcant source of morbidity and mortality with high
clinical and economic costs (1–3). Percutaneous balloon
angioplasty of the superﬁcial femoral artery and popliteal
lesions is effective at acutely restoring ﬂow, but restenosis
occurs in 40% to 60% of patients within 1 year, leading to
therapeutic failure and reintervention (4–7). Bare nitinol stents
have improved outcomes, with a reduction in 1-year restenosis
rates of 20% to 40% (8–11), but durability of patency after
existing percutaneous treatment options remains a clinical
challenge.
Drug-coated balloons (DCB) offer a mechanism to
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studies demonstrate even limited exposure of smooth
muscle to paclitaxel yields sustained inhibition of prolifer-
ation (12,13). The ﬁrst effective DCB dissolved paclitaxel
in organic solvents with the contrast agent iopromide
to facilitate application to the balloon (13,14). Early
randomized clinical studies in both coronary (15,16) and
peripheral (17,18) vascular beds suggest that angioplasty
balloons coated with 3 mg/mm2 paclitaxel formulated
with iopromide are effective at inhibiting restenosis.
A wide variety of drug-release proﬁles and restenosis
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12(19–22). Similarly, different outcomes have been reported
for DCB formulations containing similar amounts of
paclitaxel in animal models (23,24) and human clinical trials
(25,26), highlighting the criticality of formulation for local
paclitaxel delivery.
The purpose of this randomized study is to evaluate the
biologic effect and estimate potential clinical outcomes with
use of the Lutonix DCB technology with 2 mg/mm2 pacli-
taxel formulated with polysorbate and sorbitol in the
superﬁcial femoral or popliteal arteries by direct comparison
to uncoated balloon angioplasty. As a measure of anti-
restenotic effect, angiographic late lumen loss (LLL) was
selected as the primary endpoint for consistency with
previous DCB studies (15–18).
Methods
Design and study population. LEVANT I (Lutonix Pacli-
taxel-Coated Balloon for the Prevention of Femoropopliteal
Restenosis) was a prospective, single blind (to patient),
randomized (1:1) trial comparing LLL in femoropopliteal
lesions treated with the Lutonix DCB versus an uncoatedAbbreviations
and Acronyms
DCB = drug-coated balloon(s)
ITT = intention to treat
LLL = late lumen loss
PK = pharmacokinetics
TLR = target lesion
revascularization(s)balloon. Lesion criteria for
enrollment included single de
novo or (non–in-stent) restenotic
lesions (operator-determined
>70% stenosis; length 4 cm
and 15 cm; reference vessel
diameter 4 mm and 6 mm).
Eligible participants were 18
years old with Rutherford clinical
category 2 to 5 claudication orcritical limb ischemia. Exclusions included the following: life
expectancy 2 years; creatinine >2.5 mg/dl or history of
hemorrhagic stroke 3 months; previous surgery of the
target lesion; previous or planned intervention 30 days; use
of adjunctive therapies (including glycoprotein IIb/IlIa
inhibitors); severe lesion calciﬁcation; sudden symptom
onset; acute or subacute target vessel thrombus or occlusion;
absence of 1 patent untreated runoff vessel; or signiﬁcant
inﬂow disease. The study was conducted in full compliance
with International Conference on Harmonization Good
Clinical Practice, ISO 14155, and the Declaration of Hel-
sinki, and with approval of the local ethics committee.
Study enrollment and randomization. Subjects were strati-
ﬁed after pre-dilation (to less than reference vessel diameter)
based on whether the interventionalist intended to use only
balloon dilation of the lesion or intended concomitant
stenting. After successful pre-dilation or stenting, subjects in
each stratum (intended balloon-only or intended stenting)
were randomized 1:1 to Lutonix DCB or uncoated balloon
(control group) using sequentially numbered sealed envelopes
in blocks of 4 via computer-generated random numbers
(Integra Group, Brooklyn Park, Minnesota).Study device. The Lutonix DCB is a low-dose DCB coated
with 2 mg/mm2 paclitaxel. In addition to paclitaxel, the
coating on the Lutonix DCB contains a polysorbate/sorbitol
carrier. The carrier was selected after screening over 200
formulations for ability to achieve a highly uniform and
durable coating, to minimize drug loss during insertion and
transit to the target area, and to facilitate drug transfer with
redistribution and retention in deep layers of the arterial
wall.
Procedure. Angioplasty was performed according to the
standard procedure at the investigational site. The Lutonix
DCB (Lutonix, Inc., a subsidiary of C. R. Bard, New Hope,
Minnesota) was provided in diameters of 5.0 mm and 6.0
mm and lengths of 60 mm and 100 mm. Operators were
instructed to ensure DCB placement proximally and distally
beyond the margins of the pre-dilated injury segment, to
inﬂate within 3 min of insertion, and to maintain inﬂation
for 30 s. If 2 balloons were needed, the marker bands of
each sequentially used DCB were overlapped for complete
lesion and margin coverage. In the control group, off-the-
shelf percutaneous balloon angioplasty balloons were used
for dilation. To control bias, bailout nitinol stenting in the
intended balloon-only stratum was permitted in either
group only for grade C or greater dissections or occlusive
complications.
Device success was deﬁned as successful delivery and
deployment of the ﬁrst inserted study device at the intended
target lesion and withdrawal of that study device with attain-
ment of <30% ﬁnal residual stenosis of the target lesion by
quantitative angiography. Procedural success was investigator-
reported completion of the procedure with <30% residual
stenosis of the target lesion after prolongeddilation and stenting,
if necessary.
Study medication regimens and schedules were according
to local clinical practice with aspirin (100 to 325 mg per day
indeﬁnitely) and clopidogrel loading dose (75 or 300 mg)
with maintenance for 1 month in balloon-only subjects and
3 months in stented subjects.
Primary endpoint. The primary outcome was angiographic
LLL at 6 months in the analysis segment (entire length of
the balloon inﬂation area [the injury segment] plus 5-mm
proximal and distal margins) as assessed by independent,
blinded angiographic core lab analysis (genae associates,
Antwerp, Belgium).
Study outcomes and follow-up. Clinical follow-up was
conducted at 1, 6, 12, and 24 months after the procedure.
Angiography of the target limb was performed at index
procedure and 6 months after the procedure. Duplex ultra-
sound, Rutherford classiﬁcation, ankle brachial index, and
walking impairment questionnaire were evaluated at base-
line, 6, 12, and 24 months. Primary patency rates were based
on freedom from target lesion revascularization (TLR) and
from angiographic binary restenosis >50% at 6 months or
Doppler ultrasound peak systolic velocity ratio 2.5 at 12
Figure 1. CONSORT Flow Diagram
Participant ﬂow through the trial as shown, including stratiﬁcation, treatment allocation, follow-up compliance, and analysis. CA ¼ cancer; DUS ¼ Doppler ultrasound;
LTFU ¼ lost to follow-up; MI ¼ myocardial infarction; PTA ¼ percutaneous balloon angioplasty.
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13and 24 months. Major adverse events were independently
adjudicated by a Clinical events committee, and a data safety
and monitoring board (genae associates) evaluated the
progress of the study.
Pharmacokinetic substudy. Pharmacokinetic (PK) analysis
was performed in 7 Lutonix DCB subjects on the basisof paclitaxel levels measured pre-procedure, post-procedure,
at 1 h, 3 h, and prior to discharge using WinNonlin
noncompartmental analysis (Seventh Wave Labs, Chester-
ﬁeld, Missouri; high-performance lipid chromatography
mass spectroscopy by BASi Labs, McMinnville, Oregon).
The lower limit of detection was 0.1 ng/ml.
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14Statistical analysis. Formal a priori hypothesis testing was
not performed for this feasibility study. The study required
100 subjects to provide 80% power to detect a clinically
meaningful difference in LLL of 15% of reference vessel
diameter between treatment groups on the basis of
a 2-sample Student t test with 2-sided alpha 0.05.
Descriptive statistics were used for analyses on the primary
dataset including all randomized participants in both strata
on an intention-to-treat (ITT) basis and on post-hoc
groups with successful and failed deployment. Continuous
variables are presented as mean  SD, with Student t tests.
Nonparametric testing was also conducted, and no differ-
ences in conclusions compared with those of the parametric
tests were observed. Categorical variables are presented as
number and percentage of subjects, with chi-square tests.Results
Enrollment and follow-up. Between June 26, 2009 and
December 2, 2009, 101 subjects were enrolled at 9 clinical
sites; 49 subjects were randomized to Lutonix DCB and 52Table 1. Baseline Demographic and Lesion Characteristics
Lutonix DCB
(n ¼ 49)
Uncoated Balloon
(n ¼ 52) p Value
Age, yrs 67  8 70  10 0.08
Male 34 (69) 30 (58) 0.22
Smoking, current 15 (31) 20 (39) 0.69
Type 2 diabetes mellitus 22 (45) 26 (50) 0.61
Hypertension 47 (96) 45 (87) 0.10
Dyslipidemia 29 (59) 36 (69) 0.29
Previous coronary artery disease 19 (39) 23 (44) 0.58
Peripheral vascular parameters
History of peripheral vascular
disease
32 (65) 28 (54) 0.24
Baseline Rutherford category 0.80
2 11 (22) 11 (21)
3 35 (72) 37 (71)
4 1 (2) 2 (4)
5 2 (4) 2 (4)
Ankle-brachial index
(treated side)
0.69  0.23 0.60  0.36 0.18
Baseline lesion characteristics
Target lesion location 0.62
Superﬁcial femoral artery 45 (92) 49 (94)
Popliteal artery 4 (8) 3 (6)
Reference vessel diameter, mm* 4.1  0.6 4.2  0.7 0.44
In-segment diameter stenosis, %* 85.2  16.5 85.3  17.4 0.98
Lesion length, mm* 80.8  37.0 80.2  37.8 0.89
De novo lesions 44 (90) 46 (88) 0.83
Total occlusions 20 (41) 22 (42) 0.88
Values are mean  SD or n (%). *Quantitative vascular angiography measurements.
DCB ¼ drug-coated balloon.to uncoated balloons (control) as shown in Figure 1. The
intended balloon-only stratum had 75 subjects and the
intended stenting stratum had 26 subjects.
Demographics and peripheral vascular disease history.
Demographic, medical history, peripheral vascular disease
status and lesion characteristics (Table 1) were matched
between the 2 groups. Mean lesion length was 80.5 mm
with 89% de novo lesions. High complexity was evident with
42% total occlusions and 7% popliteal lesions.
Procedural outcomes. Treatment balloon deployment
parameters (Table 2) were comparable between the Lutonix
DCB and uncoated balloon groups, with mean deployment
pressures of 9 atm and inﬂation durations of approximately
100 s (protocol mandated 30 s for drug delivery in the
DCB group). Overall stent usage was similar in both
randomized groups (p ¼ 0.20), although bailout stenting of
subjects in the intended balloon-only stratum was more
frequent for the control than the DCB group. The rate of
dissections was similar for both randomized groups, but
the percentage of dissections that were treated was higher
for the control than for the DCB group (80% vs. 33%,
p ¼ 0.04).
Device success as assessed by the core lab was lower in
the DCB group because of 8 malfunctions resulting in
failed deployments. The early failed deployments wereTable 2. Procedural Outcomes
Lutonix DCB
(n ¼ 49)
Uncoated Balloon
(n ¼ 52) p Value
Pre-dilation
%DS after pre-dilation (to less
than reference vessel diameter)
48  20 46  18
Study balloon deployment
Maximal pressure pre-dilation
balloon, atm
10  2 9  2
Balloon deployment pressure, atm 9  2 9  2
Inﬂation duration, s 109  61 96  64
Balloon malfunctions 8 (16) 0 (0)
Device success, core lab assessed 27 (55) 37 (71) 0.09
Adjunctive procedural steps
Dissections after randomized
treatment
9 (18) 10 (19) 0.90
Treated dissections 3/9 (33) 8/10 (80) 0.04
Bailout stenting, balloon-only
stratum
1/37 (3) 6/38 (16) 0.05
Total stent use, intended and
provisional
13 (27) 20 (38) 0.20
Procedural outcomes
Procedural success 49 (100) 51 (99) 0.53
SAE through discharge 2 3 0.74
SAE through 30 days 9 10 0.91
Values are mean  SD, n (%), or n/N (%).
DCB ¼ drug-coated balloon; DS ¼ diameter stenosis; SAE ¼ serious adverse events.
Figure 2. Serum Paclitaxel Concentrations
Mean concentration at each time point (0, 1, and 3 h post-procedure and just
prior to discharge) are shown with error bars for standard deviation of
concentration (vertical) and sample collection time (horizontal). Sample size
(n), peak concentration (Cmax), total observed exposure (AUCall), and mean
residence time to last measurable concentration (MRTlast) of paclitaxel in
serum are shown.
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15obvious to the operator at the time; the devices were easily
removed from the body; and adjunctive measures led to
100% procedural success without safety complications.
Investigation showed that 8 of 8 deployment failures were
because of a manufacturing defect with twisted balloon
folds that prevented proper balloon inﬂation and expansion.
Investigative sites were trained to visually inspect the
balloons prior to insertion and to not use abnormally folded
balloons.
Pharmacokinetics. Mean paclitaxel concentrations for the 7
subjects treated with 10 DCB in the PK substudy are pre-
sented in Figure 2. The paclitaxel PK exhibited the expected
biexponential decay with a rapid distribution phase followed
by a log-linear elimination phase. Group mean values were
as follows: peak concentration (Cmax) ¼ 58.4  83.2 ng/ml;
total observed exposure (AUCall) ¼ 73.2  45.3 ng h/ml;
and mean residence time to last measurable concentration
(MRTlast) ¼ 5.6  4.6 h.
Primary endpoint. Six-month angiographic follow-up for
the primary endpoint was available for 39 patients (80%) in
the Lutonix DCB group and 36 (69%) in the uncoated
balloon group, due in part to 4 deaths and 5 withdrawals. By
ITT analysis (Fig. 3), the 6-month primary LLL endpoint
was signiﬁcantly lower in the Lutonix DCB group than in the
uncoated balloon group (0.46 1.13mmvs. 1.09 1.07mm,
p¼ 0.016). The difference in LLLbetween theLutonixDCB
and uncoated balloon groups was also signiﬁcant in the
intended balloon-only stratum (0.45  1.18 mm vs. 1.19
 1.15mm, p¼ 0.024). In the intended stenting stratum, theLLL for the DCB group was 0.49 1.01mm compared with
0.90  0.91 mm for the uncoated balloon group without
statistical signiﬁcance at this sample size (n ¼ 8 vs. 11).
Safety outcomes. Safety and functional outcomes at 6, 12,
and 24 months are shown in Table 3, without obvious
differences between the groups on an ITT basis. In the
DCB group, there were no thromboses, 1 amputation (with
subsequent death), and 4 deaths (adjudicated as due to
cancer [1], sepsis [1], and cardiac [2] causes). In the
uncoated balloon group, there were 1 thrombosis, no
amputations, and 5 deaths (adjudicated as due to cancer [1]
and cardiac [4] causes). To 24 months, there were 15 TLR
in the Lutonix DCB group compared with 20 TLR in the
uncoated balloon group (p ¼ 0.23). Composite major ad-
verse event rate of death, thrombosis, amputation, and
reintervention was 39% (19 of 49) for the Lutonix DCB
group compared with 46% (24 of 52) for the uncoated
balloon group (p ¼ 0.45).
Successful deployment outcomes. As shown in Table 4,
subjects with successful Lutonix DCB deployment, deﬁned
as full expansion and apposition to the vessel wall, had LLL
of 0.39  1.11 mm, whereas subjects with failed deployment
had LLL of 0.71  1.27. Primary patency at 24 months was
66% for subjects with successful deployment versus 0% for
failed deployment (p ¼ 0.002). Only 24% of subjects with
successful DCB deployment had a TLR through 24 months,
versus 63% of those with failed deployments (p ¼ 0.031).
Figure 4 shows Kaplan-Meier event-free survival for the
Lutonix DCB group with successful balloon deployment
versus for the uncoated balloon control group.
Geographic miss was identiﬁed in 14 subjects with DCB
misplacement such that the drug was not delivered to the
entire target lesion or pre-dilation injury segment. The post
hoc DCB cohort treated with successfully deployed balloons
without geographic miss had 6-month LLL of 0.18  0.99
(n ¼ 23), and 24-month primary patency of 73% (19 of 26)
and TLR rate of 19% (5 of 26) (data not shown).
Discussion
This randomized study provides the ﬁrst human proof of
the antirestenotic effect of the Lutonix DCB in treating
lower extremity occlusive disease, with a 58% reduction in
6-month LLL for the Lutonix DCB-treated group versus
the uncoated balloon control group (0.46 vs. 1.09 mm).
These ﬁndings compare well to ﬁrst-generation DCB
where higher doses of paclitaxel (3 mg/mm2) resulted in
mean LLL of 0.4 mm (17) and 0.5 mm (18), despite the
fact that the vessels treated in this study had smaller
diameter with longer lesion length and a higher frequency
of total occlusion. The antirestenotic beneﬁt of DCB was
observed when used alone or in combination with stents.
Safety in this patient population persisted out to 24
months.
All Subjects Balloon Group Stent Group
La
te
 L
um
en
 L
os
s 
(m
m
)
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
1.
4 Lutonix DCB
Uncoated Balloon
N=39 N=35 N=31 N=24 N=8 N=11
0.46±1.13
1.09±1.07
0.45±1.18
1.19±1.15
0.49±1.01
0.9±0.91
P=0.016
P=0.024
P=0.37
N
um
be
rs
 s
ho
w
n 
as
 m
ea
n±
S
D
Figure 3. Primary Endpoint
Mean late lumen loss at 6 months is shown for Lutonix drug-coated balloon (DCB) (open bars) versus control uncoated balloon percutaneous balloon angioplasty
(solid bars) in the intention-to-treat population (all subjects in pooled strata) and separately for each stratum (intended balloon or stent groups) with p values.
Columns are labeled with evaluable sample size (n) at base and mean late lumen loss  SD (mm) at top.
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16The Lutonix DCB uses polysorbate and sorbitol as the
drug carrier selected to evenly distribute the paclitaxel in
a uniform, durable coating for endovascular drug transfer. PK
analysis showed transient serum levels after treatment
with the Lutonix DCB that are much lower than those
reported for pharmaceutical infusions, with comparable
elimination (27).Table 3. Cumulative Clinical Outcomes Through 6, 12, and 24 Months of Follow
6 Months
DCB
(n ¼ 47)
Uncoated Balloon
(n ¼ 45)
Cumulative clinical events
Target vessel revascularization 6 (13) 11 (24)
Target lesion revascularization 6 (13) 10 (22)
Thrombosis in target vessel 0 (0) 1 (2)
Amputation 1 (2)* 0 (0)
Death 1 (2)* 3 (6)
Primary patencyy 28/39 (72) 17/41 (49)
Clinical assessments
Improvement in ABI from baseline 0.20  0.34 (44) 0.22  0.33 (38)
Rutherford class improvement from baseline 1.7  1.3 (45) 1.6  1.5 (42)
WIQ improvement from baseline 35.3  32.5 (26) 36.0  35.1 (25)
Values are n (%), n/N (%), or mean  SD. *Amputation and death occurred in the same subject. yPrim
angiography (>50%DS) at 6 months, and by PSVR 2.5 at 12 and 24 months.
ABI ¼ ankle brachial index; PSVR ¼ peak systolic velocity ratio; WIP ¼ walking impairment questionDeployment success predicts effective drug transfer. In the
DCB group, 8 subjects had failed balloon deployment due
to a balloon malfunction that prevented full vessel wall
apposition. Future lots used a different manufacturing
process to resolve this issue, and investigative sites were
trained to identify and not use defectively folded balloons.
In this group with suboptimal drug delivery and possible-Up
12 Months 24 Months
DCB
(n ¼ 45)
Uncoated Balloon
(n ¼ 42)
DCB
(n ¼ 42)
Uncoated Balloon
(n ¼ 41)
13 (29) 15 (37) 15 (36) 21 (51)
13 (29) 14 (33) 15 (36) 20 (49)
0 (0) 1 (2) 0 (0) 1 (2)
1 (2)* 0 (0) 1 (2)* 0 (0)
2 (4)* 4 (9) 4 (9)* 5 (11)
30/45 (67) 23/42 (55) 24/42 (57) 17/43 (40)
0.18  0.30 (42) 0.20  0.46 (38) 0.20  0.34 (37) 0.18  0.33 (32)
1.6  1.3 (45) 2.1  1.3 (38) 2.1  1.1 (39) 1.8  1.1 (33)
29.7  26.1 (28) 34.6  35.3 (23) 40.8  29.5 (19) 40.3  32.0 (21)
ary patency based on freedom from target lesion revascularization and restenosis, restenosis by
naire; other abbreviations as in Tables 1 and 4.
Table 4. Outcomes for Successful and Failed DCB Deployment
Successful DCB
Deployment
(n ¼ 41)
Failed DCB
Deployment
(n ¼ 8)
Acute procedure
Post pre-dilation dissection 39 38
Balloon deployment pressure, atm 8.35  1.65 9.00  2.39
Inﬂation duration, s 106  59 96  56
Planned stenting 27 13
Bail out stenting 0 0
Procedural complications 0 0
Efﬁcacy
6-month late lumen loss, mm 0.39  1.11 (31) 0.71  1.27 (8)
6-month primary patency, angiography 25/31 (81) 3/8 (38)
12-month primary patency, PSVR 2.5 28/37 (76) 2/8 (25)
24-month primary patency, PSVR 2.5 23/35 (66) 0/7 (0)
12-month safety, cumulative
Target lesion revascularization 8 (20) 5 (63)
Target vessel thrombosis 0 (0) 0 (0)
Amputation 1 (2)* 0 (0)
Death 2 (5)* 0 (0)
24-month safety, cumulative
Target lesion revascularization 10 (24) 5 (63)
Target vessel thrombosis 0 (0) 0 (0)
Amputation 1 (2)* 0 (0)
Death 4 (10)* 0 (0)
Values are %, mean  SD, mean  SD (n), n/N (%), or n (%). *Amputation and death occurred in
the same subject.
Abbreviations as in Tables 1 and 3.
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Figure 4. Kaplan-Meier Curves
Freedom from loss of patency, thrombosis, amputation, and death for Lutonix
drug-coated balloon (DCB) treatment (solid line) and uncoated balloon
percutaneous balloon angioplasty control (dashed line) for subjects with
successful device deployment. Number of subjects at risk over time is
provided below curves.
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17vascular trauma, 6-month LLL was higher, patency was 0,
and 24-month TLR was higher than that seen in subjects
with successful DCB deployment. The observation that
DCB subjects treated with successfully deployed balloons
without geographic miss had a high degree of primary
patency (73%) and a low TLR rate (19%) through 24
months provides evidence that optimum drug delivery to the
target area of the vessel wall is critical for sustained
prevention of restenosis.
Lutonix DCB antirestenotic beneﬁt in intended balloon-only
or intended stenting strategies. A simple but novel design
element of LEVANT I was stratiﬁcation into intended
stenting versus intended balloon-only groups after pre-
dilation but before randomization. The merits of this design
are that it balances out differences in stent use, sequence of
DCB use (before or after stenting), and risk proﬁles between
the DCB and uncoated balloon groups. The intended
balloon-only strata included subjects with post pre-dilation
residual stenosis <70%, where it was judged that stenting
was unlikely. For this stratum, Lutonix DCB reduced LLL
by 62% compared with LLL for uncoated control balloons.
The intended stenting stratum included subjects with ﬂow-
limiting dissections or stenosis 70% after pre-dilation.
This stratum had a smaller sample size, and although meanLLL trended 48% lower for DCB, a difference between
arms was not observed.
Safety and clinical outcomes to 24 months. This study was
designed to measure angiographic LLL and was not pow-
ered to assess clinical outcomes. However, use of the DCB
did not increase major adverse events (composite or indi-
vidually) when compared with those seen with the use of
uncoated balloons. No target vessel thromboses were
observed in the Lutonix DCB group, a historic concern for
local vascular delivery. On an ITT basis, the TLR rate
appears higher for the DCB group than was observed in
other randomized DCB studies reporting TLR rates of 15%
(17) and 13% (18). However, differences between trials in
lesion length, stent use, event deﬁnitions, censoring, clinical
trial rigor, and variability in angiographic follow-up make
direct comparisons difﬁcult. The present study was also
complicated by the 8 deployment malfunctions. All 3 studies
met their primary endpoint of decreased angiographic LLL
for DCB.
Study limitations. LEVANT I was a single blind design.
Although angiographic entry and stratiﬁcation criteria were
operator-determined prior to randomization, potential post-
randomization procedural and follow-up bias cannot be
precluded for unblinded operators. Only limited balloon
sizes were available, and the protocol-mandated angiograms
at 6 months may have confounded clinical follow-up. The
study was limited by small sample size for evaluating binary
Scheinert et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 1 , 2 0 1 4
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18outcomes such as clinical events or patency. Runoff was not
compared between the 2 study groups. An unexpected
limitation to the study was the balloon deployment mal-
functions, with poorer late outcomes in the subgroup with
failed deployment that diluted the ITT analysis. Despite the
clear failure of drug delivery in this subset of subjects, safety
and primary endpoint treatment effect were still evident on
an ITT basis.
Conclusions
These data demonstrate the safe use of the low-dose Lutonix
DCB to attenuate restenotic responses across various
procedural approaches (DCB used alone, with provisional
stenting, or after stenting) out to 24 months. Treatment of
femoropopliteal lesions with the novel Lutonix DCB is
feasible, with similar safety and less LLL than has been
reported for uncoated balloon angioplasty.
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